AstraZeneca’s Imfinzi Fails to Meet its Primary Endpoints in P-III KESTREL Study

 AstraZeneca’s Imfinzi Fails to Meet its Primary Endpoints in P-III KESTREL Study

AstraZeneca’s Imfinzi Fails to Meet its Primary Endpoints in P-III KESTREL Study

Shots:

  • The P- III KESTREL trial involves assessing of Imfinzi (durvalumab) or Imfinzi + tremelimumab vs EXTREME treatment regimen (CT+ cetuximab) in patients as a 1L treatment for patients with recurrent or m-HNSCC whose tumors expressed high levels of PD-L1
  • The trial failed to meet its 1EPs of improving OS while the combination did not indicate an OS benefit in all-comer patients as 2EPs. The safety & tolerability for Imfinzi as a monothx. and in combination were consistent with previous trials
  • Imfinzi is a human mAb that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: New Europe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post